APA (7th ed.) Citation

He, Q., Bu, F., Zhang, H., Wang, Q., Tang, Z., Yuan, J., . . . Xiang, X. (2021). Investigation of the Impact of CYP3A5 Polymorphism on Drug–Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling. Pharmaceuticals, 14(3), 198. https://doi.org/10.3390/ph14030198

Chicago Style (17th ed.) Citation

He, Qingfeng, Fengjiao Bu, Hongyan Zhang, Qizhen Wang, Zhijia Tang, Jing Yuan, Hai-Shu Lin, and Xiaoqiang Xiang. "Investigation of the Impact of CYP3A5 Polymorphism on Drug–Drug Interaction Between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling." Pharmaceuticals 14, no. 3 (2021): 198. https://doi.org/10.3390/ph14030198.

MLA (9th ed.) Citation

He, Qingfeng, et al. "Investigation of the Impact of CYP3A5 Polymorphism on Drug–Drug Interaction Between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling." Pharmaceuticals, vol. 14, no. 3, 2021, p. 198, https://doi.org/10.3390/ph14030198.